3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mucopolysaccharidosis I
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Liposarcoma
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Immunoblastic Lymphadenopathy
1
Gastro-enteropancreatic neuroendocrine tumor
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
26
Nivolumab
10
Cisplatin
9
Gemcitabine
8
Docetaxel
6
enfortumab vedotin
5
atezolizumab
5
Ipilimumab
5
Carboplatin
5
sacituzumab govitecan
4
Paclitaxel
4
Pemetrexed
3
Cyclophosphamide
3
vofatamab
2
tremelimumab
2
tislelizumab
2
regorafenib
2
lenvatinib
2
epacadostat
2
durvalumab
2
avelumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Biopsy
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
ALT-803
2
yeast-CEA vaccine
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Transitional Cell
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled